Poliomyelitis is an acute communicable disease of humans caused by human enterovirus called poliovirus. Poliovirus is transmitted from one person to another by oral contact, with secretions or fecal material from an infected person. Wild type poliovirus cases have been decreased by over 99% since 1988, according to World Health Organization (WHO), March 2018 report. Though most of the countries such as the U.S. and India are polio free still endemic transmission of virus is continuing in Afghanistan, Nigeria, and Pakistan, owing to failures in implementing strategic approaches such as proper immunization. These factors are demanding for newer poliomycetes vaccines for disease treatment, which is expected to drive growth of the market.
Rising number of mergers and acquisitions of key players in the poliovirus vaccine industry is expected to rise growth of the poliomycetes vaccine in dragee candy market. For instance, in April 2017, Serum Institute of India Pvt. Ltd., acquired Nanotherapeutics, a Czech company for US $ 82.08 million. This acquisition by Serum Institute aided in expanding injectable polio vaccine manufacturing capacity to 200 million dosages, making the company the largest manufacturers of polio vaccines in the world.
PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2310
Furthermore, in July 2018, Bharat Biotech announced to develop polio vaccine against type I and III viruses. Bharat Biotech is looking at combination vaccines inclusive of the Sabin Inactivated Polio Vaccine (sIPV) for successful eradication of poliovirus. Such robust manufacturing of vaccines against poliovirus will be helpful in driving growth of the market.
Significant failures in meeting sterile conditions are leading to product recalls, which is hampering growth of poliomycetes vaccine in the market. For instance, in October 2018, Ministry of Health and Family Welfare of India recalled all batches of bivalent oral polio vaccine vials manufactured by Bio-Med Limited. Bivalent oral polio vaccine contains two types of viruses. A particular batch was contaminated with type II poliovirus and affected children.
Asia Pacific is expected to hold the leading position in the poliomycetes vaccine in dragee candy market due to increased involvement of government initiatives. For instance, Government of India is conducting mass vaccination campaigns against polio, using bivalent oral polio vaccine (bOPV) to maintain high immunity against polio. The ministry of health and family welfare is also targeting mobile and migratory population from neighboring countries to prevent re-emergence of polio.
North America is likely toperceive extensive growth in the global poliomycetes vaccine in dragee candy market, owing to rise in government funds to eradicate diseases. For instance, in December 2015, the U.S. Congress approved a total of US$ 228 million for the 2016 federal budget to support global polio abolition efforts in furtherance of the country’s long-lasting leadership to fight for polio. These funds will support ongoing efforts to stop wild poliovirus transmission in the remaining polio endemic countries.
Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2310
Key players operating in poliomycetes vaccine in dragee candy market include, China National Biotec Group Company Limited, Serum Institute of India Pvt. Ltd., Sanofi Pasteur SA, United Pharma Industries Co., Ltd., Gansu Conbest Biotech Co., Ltd., and Shenzhen Mellow Hope Pharm Industrial Co Ltd.